PURPOSE To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics.
INTRODUCTION
Systemic mastocytosis (SM) is characterized by expansion of clonal mast cells that infiltrate various organ systems. The extent of organ infiltration and subsequent organ damage serve as a basis for the WHO classification of SM as indolent SM or advanced SM (AdvSM). AdvSM includes patients with SM and an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and mast cell leukemia (MCL). [1] [2] [3] [4] SM-AHN (70% to 80% of all patients with AdvSM) is the most heterogeneous and clinically challenging subtype. The AHN usually resembles a myeloid neoplasm (eg, chronic myelomonocytic leukemia, myelodysplastic/myeloproliferative neoplasm unclassifiable, chronic eosinophilic leukemia, or myelodysplastic syndrome). In the vast majority of patients, the phenotypically most important somatic mutation (ie, KIT D816V) is detectable in the clonal mast cell compartment and in cells derived from the AHN. 5, 6 The WHO classification is most widely used for prognostication and has been validated in multiple studies. In contrast to indolent SM, AdvSM has a poor prognosis. 7 The overall survival (OS) of patients with AdvSM ranges from a few months to several years, with a median OS of approximately 4 years. 8, 9 A number of clinical, serologic, cytomorphologic, immunologic, and molecular parameters have been reported to be of (WHO-independent) prognostic significance in patients with AdvSM. 10, 11 Recent data, however, have highlighted that the molecular landscape of AdvSM is complex, with at least one somatic mutation in addition to KIT D816V (eg, in ASXL1, CBL, JAK2, RUNX1, SRSF2, or TET2) being present in more than 60% of patients with AdvSM. 12, 13 In more recent studies, several groups examined the prognostic impact of these mutations. The presence and number of additional molecular mutations, notably in SRSF2, ASXL, and/or RUNX1 (S/A/R), have a strong adverse influence on progression (leukemic transformation) to secondary MCL and/or secondary acute myeloid leukemia (AML), response to treatment, and OS. [8] [9] [10] [13] [14] [15] To date, the independent prognostic value of most variables and proposed risk scores has been derived from relatively small sets of patients, and they have not been confirmed or validated. 14 In this study, we evaluated a large cohort of clinically, morphologically, and genetically well-characterized patients with AdvSM who were enrolled in the German Registry on Disorders of Eosinophils and Mast Cells with the aim to establish a risk score integrating both clinical and molecular characteristics. The proposed clinical risk score (CRS) and mutation-adjusted risk score (MARS) were subsequently validated in an independent cohort of patients with AdvSM derived from several centers within the European Competence Network on Mastocytosis (ECNM).
PATIENTS AND METHODS

Patients
A total of 383 patients with AdvSM were included. For the training set, 231 patients with AdvSM were recruited from the German Registry on Disorders of Eosinophils and Mast Cells between 2003 and 2018, with a final update performed in November 2018. The diagnosis of AdvSM (SM-AHN, ASM, or MCL) was established according to the WHO classification. 1, 4 For the training set, bone marrow (BM) biopsies and BM smears were evaluated by reference pathologists from the ECNM (H.-P.H. and K. Sotlar). The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board of the Medical Faculty of Mannheim, Heidelberg University (Heidelberg, Germany). All patients gave written informed consent. The validation set included 152 patients from multiple centers of excellence for mastocytosis in the United States (Stanford, CA) and Europe (Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; Vienna, Austria; and Freiburg, Germanyall members of the ECNM).
Mutational and Cytogenetic Analyses
Molecular analyses were performed at diagnosis of AdvSM (prospectively or retrospectively). Targeted next-generation sequencing was performed by either 454 FLX amplicon chemistry (Roche, Penzberg, Germany) or library preparation on the basis of the TruSeq Custom Amplicon Low Input protocol (Illumina, San Diego, CA) and sequencing on the MiSeq instrument (Illumina) to investigate the mutation status of KIT and the following 32 genes : ASXL1, BCOR,  CALR, CBL, CSNK1A1, DNMT3A, ETNK1, ETV6, EZH2,  FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KRAS, MLL, MPL,  NPM1, NRAS, PHF6, PIGA, PTPN11, RUNX1, SETBP1,  SF3B1, SRSF2, TET2, TP53 , U2AF1, ZRSR2, and WT1. 12 Subsequent to bcl2fastq and demultiplexing, alignment and variant calling were performed using JSI SeqNext v4.4.0 (JSI Medical Systems, Kippenheim, Germany) software with default parameters. Only base calls with a quality score of greater than 30 were considered for additional processing. A median of approximately 1,800 reads were aligned to the target region. All regions below the minimal coverage of 400 reads were rejected and resequenced for higher depth. Variants were called with a variant allele frequency cutoff of 3%, and each was assessed manually for pathogenicity. Mutation assessment was performed using the Catalogue of Somatic Mutations in Cancer (v78), Single Nucleotide Polymorphism Database (v150), ClinVar (2018-07), Genome Aggregation Database (r2.0.2), and Database for Nonsynonymous Single Nucleotide Polymorphisms' Functional Predictions (v3.5). Cytogenetic analysis and reporting were performed according to the International System for Human Cytogenetic Nomenclature criteria using standardized techniques.
Statistical Analyses
All statistical analyses considered clinical and laboratory parameters obtained at the time of diagnosis or first referral to our center, which, in most instances, coincided with time of BM biopsy and study sample collection. OS analysis was considered from the date of diagnosis to date of death or last visit. Leukemia-free survival (LFS) was considered from the date of diagnosis to date of death, last visit, or progression (leukemic transformation) to secondary MCL or secondary AML. As the MARS reflected the highest concordance index (C-index), LFS analyses were examined for this score, only. OS probabilities and LFS were estimated using the Kaplan-Meier method and compared using the log-rank test in univariable analysis. For OS, a Cox proportional hazards model with a stepwise selection procedure was used to select covariates on the basis of their statistical significance (P , .05). Significant covariates were confirmed by forwardselection and backward-elimination techniques. On the basis of the magnitude of the hazard ratios (HRs) obtained from multivariable analysis, a weighted score was assigned to each significant variable for OS in the learning set. Bonferroni adjustments were made to univariable analysis with no changes to the multivariable models. The Mann-Whitney U test was used to compare continuous variables and medians of distributions. The receiver operating characteristic (ROC) curve was used to dichotomize continuous variables to define optimal cutoff values for each variable used in univariable analyses. Harrell's C-index (on the basis of the ROC) was used to evaluate the ability of the risk scores to predict outcome (C-index measures the goodness of fit of a model, with 0.5 indicating no discrimination and 1.0 indicating perfect prediction). For categorical variables, two patient groups were compared using the Fisher's exact test. All tests were two-sided, with P , .05 considered as statistically significant.
RESULTS
Characteristics
The characteristics of the training set patients (n = 231) are listed in Table 1 . The median age was 69 years, and there was a male predominance (68%). The WHO diagnosis was ASM in 30 patients (13%), SM-AHN in 181 patients (78%), and MCL (with or without AHN) in 20 patients (9%). The four most common AHN subtypes were chronic myelomonocytic leukemia, myelodysplastic/myeloproliferative neoplasm unclassifiable, chronic eosinophilic leukemia, and myelodysplastic syndrome. The median leukocyte count, hemoglobin level, and platelet count were 8.3 3 10 9 /L, 10.3 g/dL, and 115 3 10 9 /L, respectively, and the median serum tryptase level was 168 mg/L (normal value , 11.4 mg/L). Treatment modalities included midostaurin, cladribine, and sequential midostaurin followed by cladribine or cladribine followed by midostaurin in 111 patients (48%). During a median follow-up time of 2.2 years (range, 0 to 23 years), 118 patients (51%) died. Transformation to secondary MCL (43%) or secondary AML (57%) was observed in 35 patients (15%; Table 1 ).
No significant differences were seen between the training set and the validation set (n = 152) regarding sex, hemoglobin level, platelet count, alkaline phosphatase level, leukemic transformation, median follow-up time, and number of deaths (Table 1 ). In the training set, compared with the validation set, patients were significantly older (median age, 69 v 65 years, respectively), ASM was less frequent (13% v 30%, respectively), and SM-AHN was more frequent (78% v 63%, respectively). Compared with the validation set, more patients in the training set were treated with midostaurin or sequential treatment with midostaurin followed by cladribine or cladribine followed by midostaurin.
Importantly, the median OS and LFS times were not significantly different between the training and validation sets (OS, 3.8 and 4.4 years, respectively; P = .8; LFS, 3.3 and 3.5 years, respectively; P = .9; Appendix Fig A1A, online only). In addition, no differences were seen regarding OS among the four most common AHNs (Appendix Fig A3A-B , online only) and between KIT-positive and KIT-negative patients (Appendix Table A1 , online only).
Gene Mutations
In the training set, the KIT mutation status was as follows: KIT D816V (n = 214, 93%), other KIT mutations (n = 6, 2%), and KIT mutation negative (n = 11, 5%). The status of additional mutations was assessed in 190 (82%) of 231 patients. At least one additional mutation was observed in 82% of all patients. The most frequently affected genes (in $ 5% of patients) were TET2 (n = 79, 42%), SRSF2 (n = 75, 39%), ASXL1 (n = 42, 22%), RUNX1 (n = 34, 18%), JAK2 (n = 23, 12%), NRAS/KRAS (n = 17, 9%), CBL (n = 17, 9%), IDH1/2 (n = 9, 5%), SF3B1 (n = 9, 5%), and EZH2 (n = 9, 5%). The presence of at least one S/A/R mutation and of two or more S/A/R mutations was documented in 105 patients (55%) and 43 patients (23%), respectively ( Table 2 and Figs 1A to 1D ). An aberrant karyotype was detected in 27 (16%) of 168 patients. With the exception of different numbers of patients without KIT mutations (5% in the training set v 12% in the validation set), no significant differences were observed between the training and validation sets (eg, the number of S/A/ R-positive patients was comparable; Table 2 ).
Prognostic Impact of the WHO Classification
The WHO classification of AdvSM is of prognostic significance. In the training and validation sets, the median OS times were not reached and 10.1 years for ASM, 3.6 and 2.9 years for SM-AHN, and 0.8 and 0.5 years for MCL (with or without AHN), respectively. The WHO-defined intermediaterisk category of SM-AHN (n = 275, 72%) represented by far the largest group, compared with the low-risk category of ASM (n = 77, 20%) and the high-risk category of MCL (n = 31, 8%; Appendix Figs A1B and A2A-B).
Prognostic Impact of the S/A/R Gene Panel
Stratification on the basis of the presence and number of high molecular risk gene mutations (ie, S/A/R) was of significant prognostic impact. In the training and validation sets, median OS times were not reached and 10. 
Development and Validation of CRS for AdvSM
We applied a Cox proportional hazards model using the patients from the German Registry on Disorders of Eosinophils and Mast Cells in the training set (n = 231). In univariable analyses, the model included the following variables: age greater than 60 years, sex, WHO subtype, hemoglobin less than 10 g/dL, platelets less than 100 3 10 9 /L, mast cell infiltration in BM histology greater than 30%, serum tryptase greater than 150 mg/L, albumin less than 35 g/dL, alkaline phosphatase greater than the upper normal limit (UNL), and splenomegaly (palpable or radiographic, yes or no). The multivariable analysis identified the following four independent predictors of survival: age greater than 60 years (HR, 3.2; 95% CI, 1.8 to 5.9; P , .001), hemoglobin less than 10 g/dL (HR, 2.0; 95% CI, 1.3 to 3.0; P = .002), platelets less than 100 3 10 9 /L (HR, 1.7; 95% CI, 1.1 to 2.6; P = .01), and alkaline phosphatase greater than UNL (HR, 1.8; 95% CI, 1.1 to 2.9; P = .03). For assignment of individual scores, we divided the HR value of each variable by the median value of the regression coefficients of all variables in the final model (rounded to nearest 0.5 point). Accordingly, a weighted score of 1 was assigned to hemoglobin less than 10 g/dL, platelets less than 100 3 10 9 /L, and alkaline phosphatase greater than UNL, whereas a score of 1.5 was assigned to age greater than 60 years. On this basis, we generated the CRS, follows: low risk, 0 to 1.5 points; intermediate risk, 2 to 2.5 points; and high risk, 3 to 4.5 points. The model was then applied to the validation cohort ( Table 3 ). The median OS times for the training and validation sets were not reached and 12.2 years for the low-risk group (n = 98, 28%), 3.8 and 4.3 years for the intermediate-risk group (n = 111, 32%), and 2.6 and 1.8 years for the high-risk group (n = 136, 39%), respectively ( Table 3 , Figs 2C and 2D, and Appendix Fig A1D) .
Development and Validation of MARS
To appreciate the value of adding molecular information to the CRS, we applied a Cox proportional hazards model to patients for whom mutation status (including S/A/R gene status) was available (training set, n = 191). The model was started by considering the same variables used in developing the CRS and included the presence and number ‡Palpable or radiographic. §Sequential treatment with midostaurin followed by cladribine or cladribine followed by midostaurin. of high molecular risk gene mutations (zero, one, or two or more S/A/R mutations). Table 4 lists the results of univariable and multivariable analyses in the training set. The multivariable model identified the following five independent predictors of survival: age greater than 60 years (HR, 2.4; 95% CI, 1.4 to 5.0; P = .003), hemoglobin less than 10 g/dL (HR, 2.0; 95% CI, 1.3 to 3.0; P = .002), platelets less than 100 3 10 9 /L (HR, 1.7; 95% CI, 1.1 to 2.5; P = .02), presence of one S/A/R mutation (HR, 2.5; 95% CI, 1.6 to 4.5; P , .001), and presence of two or more S/A/R mutations (HR, 4.4; 95% CI, 2.1 to 7.3, P , .001). For assignment of individual scores, we divided the HR value of each variable by the median value of the regression coefficients of all variables in the final model (rounded to the nearest 0.5 point). Accordingly, a weighted score of 1 was assigned to age greater than 60 years, hemoglobin less than 10 g/dL, platelets less than 100 3 10 9 /L, and presence of one S/A/R mutation, whereas a score of 2 was assigned to the presence of two or more S/A/R mutations. These weighted scores were used to generate the following three risk groups, which compose the MARS: low-risk group, 0 to 1 point; intermediate-risk group, 2 points; and high-risk group, 3 to 5 points. The model was then applied to the validation cohort. Table 3 lists the OS times of the combined training and validation sets for the CRS and MARS.
The median OS times for the training and validation sets were not reached and 12.2 years for the low-risk group (n = 103, 31%), 3.9 and 4.4 years for the intermediate-risk group (n = 86, 26%), and 1.9 and 1.9 years for the high-risk group (n = 140, 43%), respectively ( Table 3 and Figs 2E to 2G). The MARS was also predictive for LFS. The median LFS times for the training and validation sets were not reached and 11 years for the low-risk group, 3.9 and 3.9 years for the intermediate-risk group, and 1.5 and 1.4 years for the high-risk group, respectively ( Fig 2H, Appendix Fig A2C and A2D, and Appendix Table A2 , online only).
Comparison of WHO Classification, CRS, and MARS
On the basis of ROC curve analyses, the C-index was 0.42 for the WHO classification, 0.73 for the CRS, and 0.81 for the MARS (Fig 1F) . For better comparison of the C-index between the four stratification tools (WHO, S/A/R, CRS, and MARS), we included the same samples (with fully available dataset from the training set, n = 190) across all rules. We established a cross table illustrating the distribution of patients with AdvSM in the new scoring system compared with the WHO classification ( Fig 1E) . Figure 1E Fig A1D) , and the prediction of LFS because S/A/R positivity (included in the MARS) at initial diagnosis is significantly associated with transformation to secondary MCL and AML. Seventy percent of all patients with leukemic transformation (n = 42) and available S/A/R status (n = 60) had at least one S/A/R mutation at initial diagnosis.
DISCUSSION
In clinical practice, the 2016 WHO classification of SM is widely used for prognostic purposes because of the lack of validated international risk scores. Although it robustly distinguishes indolent SM from AdvSM, its value for stratification within the various subtypes of AdvSM (OS: ASM . SM-AHN . MCL) remains suboptimal for the following three reasons: the clinical and histologic heterogeneity represented by the various subtypes of AdvSM; the imbalance of the various subtypes, with SM-AHN representing 70% to 80% of patients and ASM and MCL representing only 20% to 30% of patients; and the wide range of survival times within the subtypes of AdvSM and, in particular, within the SM-AHN variant between a few months and several years. 7, 8, 11, 16, 17 Therefore, the main goal of the current study was to devise and validate a new WHO-independent risk score for patients with AdvSM that integrates objective clinical and mutation characteristics.
The current analysis corroborates the prognostic value of the previously identified high molecular risk gene mutations, 8, 9, 13, 14, 18 especially the negative impact of S/A/R mutations. The presence and number of gene mutations in the S/A/R panel had a strong adverse impact on OS in both the training set and the validation set. The three genes (S/A/R) are among the top five most frequent mutations observed in AdvSM (and also other myeloid neoplasms) 19-21 and allow a balanced stratification into three risk cohorts.
Next, we established a CRS by defining the following four easily accessible and objective parameters on the basis of multivariable analyses: age greater than 60 years, anemia (hemoglobin , 10 g/dL), thrombocytopenia (platelets , 100 3 10 9 /L), and elevated alkaline phosphatase (. UNL). As illustrated in Figures 2C and 2D and Appendix Figure  A1D , LFS and OS were significantly different among the three risk groups. The prognostic impact of the CRS was confirmed in the validation set. The C-index of the CRS was comparable with that of the S/A/R-based stratification (0.73 v 0.74, respectively).
Finally, we combined the clinical and molecular data and generated the MARS. In multivariable analyses, age greater than 60 years, anemia (hemoglobin , 10 g/dL), thrombocytopenia (platelets , 100 3 10 9 /L), the presence of one S/AR mutation, and the presence of two or more S/A/R mutations were independent predictors for OS. On the basis of these five parameters, a simple risk scoring system was established for OS. The MARS was confirmed in the validation set and categorizes patients with AdvSM into three groups of significant size. OS times were not reached, 4.3 years, and 1.9 years for low-risk, intermediate-risk, and high-risk patients with AdvSM, respectively. According to the C-index (0.81), the MARS improves the prediction of OS compared with the WHO classification (C-index, 0.42) and the CRS (C-index, 0.73), especially for the intermediate-risk and high-risk groups. In addition, the MARS uses clinical and molecular data that are now commonly available. S/A/R positivity at initial diagnosis, which is the backbone of the MARS, is significantly associated with secondary leukemic transformation (MCL and AML), and therefore, the MARS is also predictive for LFS. Some recently published risk scores from our own group and from others also included variables such as anemia, thrombocytopenia, elevated alkaline phosphatase, and high molecular risk gene mutations. 10, 22 The pivotal strengths of the current analyses include the following: indolent SM was excluded in the prognostic models NOTE. For the CRS, a weighted score of 1 was assigned to hemoglobin less than 10 g/dL, platelets less than 100 3 10 9 /L, and alkaline phosphatase greater than UNL, whereas a score of 1.5 was assigned to age greater than 60 years. For the MARS, a weighted score of 1 was assigned to age greater than 60 years, hemoglobin less than 10 g/dL, platelets less than 100 3 10 9 /L, and presence of one S/A/R mutation, whereas a score of 2 was assigned to the presence of two or more S/A/R mutations.
Abbreviations: CRS, clinical risk score; MARS, mutation-adjusted risk score; NR, not reached; OS, overall survival; S/A/R, SRSF2, ASXL1, and/or RUNX1; UNL, upper normal limit because it has a nearly normal life expectancy; this analysis included the greatest number of clinically, morphologically, and genetically well-characterized patients with AdvSM ever reported; most patients had access to targeted treatment modalities such as midostaurin; and the vast majority of patients in the training set were diagnosed through fully centralized pathology and genetic analyses. An addition strength was the homogenous mutation profile (clinical and outcome characteristics) of the training set and the large and independent validation set (derived from centers with expertise in mastocytosis), particularly regarding the individual frequency of gene mutations in the S/A/R panel.
Although there are no data from clinical trials, the MARS may become useful for guiding selection of and predicting response to therapies. Previous data have shown that the multikinase/KIT inhibitor midostaurin has diseasemodifying activity in AdvSM, with sustained responses and more favorable outcome in patients with absence of mutations in the S/A/R gene panel and at least 25% reduction of the KIT D816V expressed allele burden after 6 months of therapy. 9, 16, 23, 24 Because the MARS low-risk cohort reflects the majority of these patients, midostaurin may be an optimal choice for these individuals. The generally poor prognosis of MARS intermediate-and high-risk patients may predict less robust responses with currently available therapies, including midostaurin monotherapy, highlighting the need for disease-modifying treatments in these higher risk cohorts. 9, 16, [23] [24] [25] Because of the significantly higher rates of leukemic transformation and inferior survival, more intensive treatment (eg, combination therapies with midostaurin that also target the AHN or use of more potent and selective second-generation KIT D816V inhibitors, followed by allogeneic stem-cell transplantation in eligible candidates) should be considered in these patients. In the largest yet reported cohort of 57 patients with AdvSM undergoing allogeneic stem-cell transplantation, treatment-related mortality was generally similar to other hematologic neoplasms. Important details included the superior outcome of myeloablative versus dose-reduced conditioning and the heterogenous survival within AdvSM, which was significantly better in SM-AHN compared with ASM or MCL. However, more data are needed, preferably generated in national and international registries, on the key questions regarding optimal timing, debulking, and conditioning strategies.
We conclude that the WHO classification remains the pivotal diagnostic tool for subtyping of SM into indolent SM and AdvSM. The MARS is a WHO-independent and complementary tool for the heterogeneous cohort of patients with AdvSM that defines three risk groups on the basis of a five-parameter risk score and that may improve up-front treatment stratification for these rare hematologic neoplasms. *In bone marrow histology. †Sequential treatment with midostaurin followed by cladribine or cladribine followed by midostaurin.
